Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2024

Open Access 01-12-2024 | Metabolic Disease and Nutrition | Case report

Report of an Iranian child with chronic abdominal pain and constipation diagnosed as glycogen storage disease type IX: a case report

Authors: Daniel Zamanfar, Seyed MohammadBagher Hashemi-Soteh, Mobin Ghazaiean, Elham Keyhanian

Published in: Journal of Medical Case Reports | Issue 1/2024

Login to get access

Abstract

Background

Glycogen storage disease type IX is a rare disorder that can cause a wide variety of symptoms depending on the specific deficiency of the phosphorylase kinase enzyme and the organs it affects.

Case presentation

A 4-and-a-half-year-old Caucasian girl was referred to our clinic with a liver biopsy report indicating a diagnosis of glycogen storage disease. Prior to being referred to our clinic, the patient had been under the care of pediatric gastroenterologists. The patient’s initial symptoms included chronic abdominal pain, constipation, and elevated liver transaminase. With the help of the pediatric gastroenterologists, cholestasis, Wilson disease, and autoimmune hepatitis were ruled out. Given that glycogen storage diseases type I and type III are the most common, we initially managed the patient with frequent feedings and a diet that included complex carbohydrates such as a corn starch supplement and a lactose restriction. Following an unfavorable growth velocity and hepatomegaly during the follow-up period, genetic analysis was conducted, which revealed a novel mutation of the phosphorylase kinase regulatory subunit beta gene— a c.C412T (P.Q138x) mutation. As the diagnosis of glycogen storage disease type IX was confirmed, the treatment regimen was altered to a high protein diet (more than 2 g/kg/day) and a low fat diet.

Conclusion

Given the mild and varied clinical manifestations of glycogen storage disease type IX, it is possible for the diagnosis to be overlooked. It is important to consider glycogen storage disease type IX in children who present with unexplained hepatomegaly and elevated transaminase levels. Furthermore, due to the distinct management of glycogen storage disease type IX compared with glycogen storage disease type I and glycogen storage disease type III, genetic analysis is essential for an accurate diagnosis.
Literature
1.
go back to reference Melis D, Pivonello R, Parenti G, Della Casa R, Salerno M, Lombardi G, et al. Increased prevalence of thyroid autoimmunity and hypothyroidism in patients with glycogen storage disease type I. J Pediatr. 2007;150(3):300–5.CrossRefPubMed Melis D, Pivonello R, Parenti G, Della Casa R, Salerno M, Lombardi G, et al. Increased prevalence of thyroid autoimmunity and hypothyroidism in patients with glycogen storage disease type I. J Pediatr. 2007;150(3):300–5.CrossRefPubMed
2.
go back to reference Ramakrishna SH, Nargund S, Kannan S. Glycogen storage disorder Type IXa and congenital hypothyroidism: a novel association. Indian J Child Health. 2020;7(11):459–61.CrossRef Ramakrishna SH, Nargund S, Kannan S. Glycogen storage disorder Type IXa and congenital hypothyroidism: a novel association. Indian J Child Health. 2020;7(11):459–61.CrossRef
3.
go back to reference Rodríguez-Jiménez C, Santos-Simarro F, Campos-Barros Á, Camarena C, Lledín D, Vallespín E, et al. A new variant in PHKA2 is associated with glycogen storage disease type IXa. Mol Genet Metab Rep. 2017;10:52–5.PubMedPubMedCentral Rodríguez-Jiménez C, Santos-Simarro F, Campos-Barros Á, Camarena C, Lledín D, Vallespín E, et al. A new variant in PHKA2 is associated with glycogen storage disease type IXa. Mol Genet Metab Rep. 2017;10:52–5.PubMedPubMedCentral
4.
go back to reference Chen MA, Weinstein DA. Glycogen storage diseases: diagnosis, treatment and outcome. Transl Sci Rare Dis. 2016;1(1):45–72. Chen MA, Weinstein DA. Glycogen storage diseases: diagnosis, treatment and outcome. Transl Sci Rare Dis. 2016;1(1):45–72.
5.
go back to reference Burda P, Hochuli M. Hepatic glycogen storage disorders: what have we learned in recent years? Curr Opin Clin Nutr Metab Care. 2015;18(4):415–21.CrossRefPubMed Burda P, Hochuli M. Hepatic glycogen storage disorders: what have we learned in recent years? Curr Opin Clin Nutr Metab Care. 2015;18(4):415–21.CrossRefPubMed
6.
go back to reference Johnson AO, Goldstein JL, Bali D. Glycogen storage disease type IX: novel PHKA2 missense mutation and cirrhosis. J Pediatr Gastroenterol Nutr. 2012;55(1):90–2.CrossRefPubMed Johnson AO, Goldstein JL, Bali D. Glycogen storage disease type IX: novel PHKA2 missense mutation and cirrhosis. J Pediatr Gastroenterol Nutr. 2012;55(1):90–2.CrossRefPubMed
7.
go back to reference Schippers H, Smit G, Rake J, Visser G. Characteristic growth pattern in male X-linked phosphorylase-b kinase deficiency (GSD IX). J Inherit Metab Dis. 2003;26(1):43–7.CrossRefPubMed Schippers H, Smit G, Rake J, Visser G. Characteristic growth pattern in male X-linked phosphorylase-b kinase deficiency (GSD IX). J Inherit Metab Dis. 2003;26(1):43–7.CrossRefPubMed
8.
go back to reference Tsilianidis LA, Fiske LM, Siegel S, Lumpkin C, Hoyt K, Wasserstein M, et al. Aggressive therapy improves cirrhosis in glycogen storage disease type IX. Mol Genet Metab. 2013;109(2):179–82.CrossRefPubMedPubMedCentral Tsilianidis LA, Fiske LM, Siegel S, Lumpkin C, Hoyt K, Wasserstein M, et al. Aggressive therapy improves cirrhosis in glycogen storage disease type IX. Mol Genet Metab. 2013;109(2):179–82.CrossRefPubMedPubMedCentral
9.
go back to reference Mathur S, Chhabra S, Parmar P, Gupta P, Singh S, Tayal M. Scholars Journal of Medical Case Reports ISSN 2347-6559 (Online). Mathur S, Chhabra S, Parmar P, Gupta P, Singh S, Tayal M. Scholars Journal of Medical Case Reports ISSN 2347-6559 (Online).
10.
go back to reference Burwinkel B, Maichele AJ, Aagenaes Ø, Bakker HD, Lerner A, Shin YS, et al. Autosomal glycogenosis of liver and muscle due to phosphorylase kinase deficiency is caused by mutations in the phosphorylase kinase β subunit (PHKB). Hum Mol Genet. 1997;6(7):1109–15.CrossRefPubMed Burwinkel B, Maichele AJ, Aagenaes Ø, Bakker HD, Lerner A, Shin YS, et al. Autosomal glycogenosis of liver and muscle due to phosphorylase kinase deficiency is caused by mutations in the phosphorylase kinase β subunit (PHKB). Hum Mol Genet. 1997;6(7):1109–15.CrossRefPubMed
11.
go back to reference Kishnani PS, Goldstein J, Austin SL, Arn P, Bachrach B, Bali DS, et al. Diagnosis and management of glycogen storage diseases type VI and IX: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2019;21(4):772–89.CrossRefPubMed Kishnani PS, Goldstein J, Austin SL, Arn P, Bachrach B, Bali DS, et al. Diagnosis and management of glycogen storage diseases type VI and IX: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2019;21(4):772–89.CrossRefPubMed
12.
go back to reference Ramakrishna SH, Nargund S, Kannan S. Glycogen storage disorder Type IXa and congenital hypothyroidism: a novel association. Indian J Child Health. 2020:459–61. Ramakrishna SH, Nargund S, Kannan S. Glycogen storage disorder Type IXa and congenital hypothyroidism: a novel association. Indian J Child Health. 2020:459–61.
13.
go back to reference Zhang J, Yuan Y, Ma M, Liu Y, Zhang W, Yao F, et al. Clinical and genetic characteristics of 17 Chinese patients with glycogen storage disease type IXa. Gene. 2017;627:149–56.CrossRefPubMed Zhang J, Yuan Y, Ma M, Liu Y, Zhang W, Yao F, et al. Clinical and genetic characteristics of 17 Chinese patients with glycogen storage disease type IXa. Gene. 2017;627:149–56.CrossRefPubMed
14.
go back to reference Roscher A, Patel J, Hewson S, Nagy L, Feigenbaum A, Kronick J, et al. The natural history of glycogen storage disease types VI and IX: long-term outcome from the largest metabolic center in Canada. Mol Genet Metab. 2014;113(3):171–6.CrossRefPubMed Roscher A, Patel J, Hewson S, Nagy L, Feigenbaum A, Kronick J, et al. The natural history of glycogen storage disease types VI and IX: long-term outcome from the largest metabolic center in Canada. Mol Genet Metab. 2014;113(3):171–6.CrossRefPubMed
15.
go back to reference Choi R, Park H-D, Kang B, Choi SY, Ki C-S, Lee S-Y, et al. PHKA2 mutation spectrum in Korean patients with glycogen storage disease type IX: prevalence of deletion mutations. BMC Med Genet. 2016;17:1–9.CrossRef Choi R, Park H-D, Kang B, Choi SY, Ki C-S, Lee S-Y, et al. PHKA2 mutation spectrum in Korean patients with glycogen storage disease type IX: prevalence of deletion mutations. BMC Med Genet. 2016;17:1–9.CrossRef
17.
go back to reference Tuchman M, Brown BI, Burke BA, Ulstrom RA. Clinical and laboratory observations in a child with hepatic phosphorylase kinase deficiency. Metabolism. 1986;35(7):627–33.CrossRefPubMed Tuchman M, Brown BI, Burke BA, Ulstrom RA. Clinical and laboratory observations in a child with hepatic phosphorylase kinase deficiency. Metabolism. 1986;35(7):627–33.CrossRefPubMed
18.
go back to reference Wolfsdorf JI, Weinstein DA. Glycogen storage diseases. Rev Endocr Metab Disord. 2003;4(1):95–102.CrossRefPubMed Wolfsdorf JI, Weinstein DA. Glycogen storage diseases. Rev Endocr Metab Disord. 2003;4(1):95–102.CrossRefPubMed
19.
go back to reference Erez A, Shchelochkov OA, Plon SE, Scaglia F, Lee B. Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism. Am J Human Genet. 2011;88(4):402–21.CrossRef Erez A, Shchelochkov OA, Plon SE, Scaglia F, Lee B. Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism. Am J Human Genet. 2011;88(4):402–21.CrossRef
21.
go back to reference Saudubray J-M. Clinical phenotypes: diagnosis/algorithms. The metabolic and molecular bases of inherited disease. 2001:1327–403. Saudubray J-M. Clinical phenotypes: diagnosis/algorithms. The metabolic and molecular bases of inherited disease. 2001:1327–403.
22.
go back to reference Davit-Spraul A, Piraud M, Dobbelaere D, Valayannopoulos V, Labrune P, Habes D, et al. Liver glycogen storage diseases due to phosphorylase system deficiencies: diagnosis thanks to non invasive blood enzymatic and molecular studies. Mol Genet Metab. 2011;104(1–2):137–43.CrossRefPubMed Davit-Spraul A, Piraud M, Dobbelaere D, Valayannopoulos V, Labrune P, Habes D, et al. Liver glycogen storage diseases due to phosphorylase system deficiencies: diagnosis thanks to non invasive blood enzymatic and molecular studies. Mol Genet Metab. 2011;104(1–2):137–43.CrossRefPubMed
23.
go back to reference Kim JA, Kim JH, Lee BH, Kim G-H, Shin YS, Yoo H-W, et al. Clinical, biochemical, and genetic characterization of glycogen storage type IX in a child with asymptomatic hepatomegaly. Pediatric Gastroenterol Hepatol Nutr. 2015;18(2):138–43.CrossRef Kim JA, Kim JH, Lee BH, Kim G-H, Shin YS, Yoo H-W, et al. Clinical, biochemical, and genetic characterization of glycogen storage type IX in a child with asymptomatic hepatomegaly. Pediatric Gastroenterol Hepatol Nutr. 2015;18(2):138–43.CrossRef
24.
go back to reference Willems P, Gerver W, Berger R, Fernandes J. The natural history of liver glycogenosis due to phosphorylase kinase deficiency: a longitudinal study of 41 patients. Eur J Pediatr. 1990;149:268–71.CrossRefPubMed Willems P, Gerver W, Berger R, Fernandes J. The natural history of liver glycogenosis due to phosphorylase kinase deficiency: a longitudinal study of 41 patients. Eur J Pediatr. 1990;149:268–71.CrossRefPubMed
25.
go back to reference Johnson AO, Goldstein JL, Bali D. Glycogen storage disease type IX: novel: PHKA2: missense mutation and cirrhosis. J Pediatr Gastroenterol Nutr. 2012;55(1):90–2.CrossRefPubMed Johnson AO, Goldstein JL, Bali D. Glycogen storage disease type IX: novel: PHKA2: missense mutation and cirrhosis. J Pediatr Gastroenterol Nutr. 2012;55(1):90–2.CrossRefPubMed
26.
go back to reference Ross KM, Brown LM, Corrado MM, Chengsupanimit T, Curry LM, Ferrecchia IA, et al. Safety and efficacy of long-term use of extended release cornstarch therapy for glycogen storage disease types 0, III, VI, and IX. J Nutr Therapeutics. 2015;4(4):137–42. Ross KM, Brown LM, Corrado MM, Chengsupanimit T, Curry LM, Ferrecchia IA, et al. Safety and efficacy of long-term use of extended release cornstarch therapy for glycogen storage disease types 0, III, VI, and IX. J Nutr Therapeutics. 2015;4(4):137–42.
Metadata
Title
Report of an Iranian child with chronic abdominal pain and constipation diagnosed as glycogen storage disease type IX: a case report
Authors
Daniel Zamanfar
Seyed MohammadBagher Hashemi-Soteh
Mobin Ghazaiean
Elham Keyhanian
Publication date
01-12-2024

Other articles of this Issue 1/2024

Journal of Medical Case Reports 1/2024 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.